NO PAZEO
*
?
NO PROBLEM!
Choose the topical prescription
treatment that delivers the
proven power of cetirizine
(active ingredient in ZYRTEC
*
)
1
• Provides fast-acting, long-lasting relief
that lubricates with every drop
2,3
• Covered on most commercial and
Medicare Part D plans
© 2021 Eyevance Pharmaceuticals LLC. All rights reserved.
ZERVIATE® is a registered trademark and HYDRELLA™ is a trademark of Eyevance Pharmaceuticals LLC.
*All other trademarks are the property of their respective owners. ZER-21-AD-106-02
INDICATIONS AND USAGE
ZERVIATE® (cetirizine ophthalmic solution) 0.24% is a
histamine-1 (H1) receptor antagonist indicated for treatment
of ocular itching associated with allergic conjunctivitis.
IMPORTANT SAFETY INFORMATION
ADVERSE REACTIONS
The most commonly reported adverse reactions occurred
in approximately 1%-7% of patients treated with either
ZERVIATE or vehicle. These reactions were ocular hyperemia,
instillation site pain, and visual acuity reduced.
Please see brief summary of Full Prescribing Information
on the adjacent page.
References: 1. ZERVIATE [package insert]. Fort Worth, TX: Eyevance
Pharmaceuticals LLC; 2018. 2. Malhotra RP, Meier E, Torkildsen G,
et al. Safety of cetirizine ophthalmic solution 0.24% for the treatment
of allergic conjunctivitis in adult and pediatric subjects. Clin
Ophthalmol. 2019;13:403-413. 3. Meier EJ, Torkildsen GL, Gomes PJ,
et al. Phase III trials examining the eff icacy of cetirizine ophthalmic
solution 0.24% compared to vehicle for the treatment of allergic
conjunctivitis in the conjunctival allergen challenge model. Clin
Ophthalmol. 2018;12:2617-2628.
that lubricates with every drop
2,3
• Covered on most commercial and
Medicare Part D plans
Available by
prescription only
Formulated with HYDRELLA™ for comfort.
1
Visit MyZERVIATE.com for more information.
For ocular itch associated
with allergic conjunctivitis
INITIATE
ZERVIATE
®
